BiotechTube

Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）

Phase 2/3Recruiting
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Radiation-induced Lung Injury

Conditions

Radiation-induced Lung Injury, Immune-related Pneumonia

Trial Timeline

Feb 28, 2026 → Oct 30, 2026

NCT ID
NCT07388680

About Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg）

Pirfenidone Capsules （400 mg） + Pirfenidone Capsules（600mg） + Pirfenidone Capsules（0mg） is a phase 2/3 stage product being developed by Sun Pharmaceutical for Radiation-induced Lung Injury. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07388680. Target conditions include Radiation-induced Lung Injury, Immune-related Pneumonia.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT07388680Phase 2/3Recruiting

Competing Products

2 competing products in Radiation-induced Lung Injury

See all competitors
ProductCompanyStageHype Score
oxetacaine, aluminium and magnesium hydroxide + oxetacaine + magnesium and aluminium hydroxideViatrisPhase 3
74
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)MeiraGTxPhase 1
25

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85